Kezar in the ignition: Fuel immunoproteasome effort with $50M

The scientific campaign for a better version of Velcade for multiple myeloma that began at Proteolix Inc. survived two mergers and ultimately failed, but led to the formation of Kezar Life Sciences Inc., with a promising approach, not to cancer but to autoimmune disorders.